JP2000509047A - ３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用 - Google Patents

３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用

Info

Publication number: JP2000509047A
Authority: JP; Japan
Prior art keywords: formula; group; compound; alkyl; hydrogen
Prior art date: 1996-04-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP09538479A

Other languages

English (en)

Japanese (ja)

Inventor

ヴアイトマン，クラウス

バーリングハウス，カール―ハインツ

チヤンク，ゲーオルク

ビツケル，マルテイン

Original Assignee

ヘキスト・アクチエンゲゼルシヤフト

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-30

Filing date

1996-04-30

Publication date

2000-07-18

1996-04-30 Application filed by ヘキスト・アクチエンゲゼルシヤフト filed Critical ヘキスト・アクチエンゲゼルシヤフト

2000-07-18 Publication of JP2000509047A publication Critical patent/JP2000509047A/ja

Status Pending legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title description 4
230000036570 collagen biosynthesis Effects 0.000 claims abstract description 10
201000010099 disease Diseases 0.000 claims abstract description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
230000003176 fibrotic effect Effects 0.000 claims abstract description 6
230000002401 inhibitory effect Effects 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 80
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 25
229910052739 hydrogen Inorganic materials 0.000 claims description 24
239000001257 hydrogen Substances 0.000 claims description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
150000002431 hydrogen Chemical class 0.000 claims description 14
-1 phenylbutyl Chemical group 0.000 claims description 14
102000008186 Collagen Human genes 0.000 claims description 11
108010035532 Collagen Proteins 0.000 claims description 11
229920001436 collagen Polymers 0.000 claims description 11
210000004185 liver Anatomy 0.000 claims description 11
230000000699 topical effect Effects 0.000 claims description 11
125000006702 (C1-C18) alkyl group Chemical group 0.000 claims description 10
206010016654 Fibrosis Diseases 0.000 claims description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 10
108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 10
230000004761 fibrosis Effects 0.000 claims description 10
230000015572 biosynthetic process Effects 0.000 claims description 9
210000004072 lung Anatomy 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
210000002808 connective tissue Anatomy 0.000 claims description 7
210000001508 eye Anatomy 0.000 claims description 7
238000001727 in vivo Methods 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 4
208000010412 Glaucoma Diseases 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
125000004344 phenylpropyl group Chemical group 0.000 claims description 4
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 4
230000002980 postoperative effect Effects 0.000 claims description 4
210000003491 skin Anatomy 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
238000011477 surgical intervention Methods 0.000 claims description 4
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
238000002512 chemotherapy Methods 0.000 claims description 3
125000004122 cyclic group Chemical group 0.000 claims description 3
210000002216 heart Anatomy 0.000 claims description 3
210000003734 kidney Anatomy 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 2
125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 2
238000009825 accumulation Methods 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
210000000056 organ Anatomy 0.000 claims description 2
125000003884 phenylalkyl group Chemical group 0.000 claims description 2
208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
230000005855 radiation Effects 0.000 claims description 2
125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
230000037390 scarring Effects 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
206010003210 Arteriosclerosis Diseases 0.000 claims 1
208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
238000007098 aminolysis reaction Methods 0.000 claims 1
230000001766 physiological effect Effects 0.000 claims 1
230000035479 physiological effects, processes and functions Effects 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
239000000203 mixture Substances 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
239000004471 Glycine Substances 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
238000000338 in vitro Methods 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
239000000047 product Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 5
HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 5
YVBCULSIZWMTFY-UHFFFAOYSA-N Heptan-4-ol Chemical compound CCCC(O)CCC YVBCULSIZWMTFY-UHFFFAOYSA-N 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
239000011734 sodium Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
NGDNVOAEIVQRFH-UHFFFAOYSA-N 2-nonanol Chemical compound CCCCCCCC(C)O NGDNVOAEIVQRFH-UHFFFAOYSA-N 0.000 description 4
MQFRBEILHZPVQG-UHFFFAOYSA-N 3-methoxypyridine-2-carboxylic acid;hydrochloride Chemical compound Cl.COC1=CC=CN=C1C(O)=O MQFRBEILHZPVQG-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
102000029816 Collagenase Human genes 0.000 description 3
108060005980 Collagenase Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
229960002424 collagenase Drugs 0.000 description 3
238000001816 cooling Methods 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
238000005984 hydrogenation reaction Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000000967 suction filtration Methods 0.000 description 3
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 2
108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 2
XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
BRARRAHGNDUELT-UHFFFAOYSA-N 3-hydroxypicolinic acid Chemical compound OC(=O)C1=NC=CC=C1O BRARRAHGNDUELT-UHFFFAOYSA-N 0.000 description 2
RYGXNMUVOHCPBF-UHFFFAOYSA-N 4-chloro-3-methoxy-2-methylpyridine Chemical compound COC1=C(C)N=CC=C1Cl RYGXNMUVOHCPBF-UHFFFAOYSA-N 0.000 description 2
208000032544 Cicatrix Diseases 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
230000003510 anti-fibrotic effect Effects 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000005805 hydroxylation reaction Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
230000037387 scars Effects 0.000 description 2
238000006748 scratching Methods 0.000 description 2
230000002393 scratching effect Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-FXLFCPKBSA-N (2S)-(214C)azolidine-2-carboxylic acid Chemical compound N1[14C@@H](CCC1)C(=O)O ONIBWKKTOPOVIA-FXLFCPKBSA-N 0.000 description 1
ISRRJUHDGVMYLE-UHFFFAOYSA-N (4-chloro-3-methoxypyridin-2-yl)methanol Chemical compound COC1=C(Cl)C=CN=C1CO ISRRJUHDGVMYLE-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
RJXVAGCQRMBMCI-UHFFFAOYSA-N 3-methoxypyridine-2-carboxylic acid Chemical compound COC1=CC=CN=C1C(O)=O RJXVAGCQRMBMCI-UHFFFAOYSA-N 0.000 description 1
TWXMQDRFBLSXFN-UHFFFAOYSA-N 4-chloro-3-methoxy-2-methyl-1-oxidopyridin-1-ium Chemical compound COC1=C(C)[N+]([O-])=CC=C1Cl TWXMQDRFBLSXFN-UHFFFAOYSA-N 0.000 description 1
HRIXILRILGXVGH-UHFFFAOYSA-N 4-chloro-3-methoxypyridine-2-carboxylic acid Chemical compound COC1=C(Cl)C=CN=C1C(O)=O HRIXILRILGXVGH-UHFFFAOYSA-N 0.000 description 1
NNMYRMGMVLMQAY-UHFFFAOYSA-N 4-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=N1 NNMYRMGMVLMQAY-UHFFFAOYSA-N 0.000 description 1
QKSKVQANRQWJIP-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;octyl 2-aminoacetate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CCCCCCCCOC(=O)CN QKSKVQANRQWJIP-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
LTYSLVSLJYMDAV-UHFFFAOYSA-N C(CCCCCCCCCCCC)OC(=O)CNC(=O)C1=NC=CC=C1OC Chemical compound C(CCCCCCCCCCCC)OC(=O)CNC(=O)C1=NC=CC=C1OC LTYSLVSLJYMDAV-UHFFFAOYSA-N 0.000 description 1
CHFUXYRNEINVLB-UHFFFAOYSA-N C(CCCCCCCCCCCCC)OC(=O)CNC(=O)C1=NC=CC=C1OC Chemical compound C(CCCCCCCCCCCCC)OC(=O)CNC(=O)C1=NC=CC=C1OC CHFUXYRNEINVLB-UHFFFAOYSA-N 0.000 description 1
AWCPKCWFUNYKJL-UHFFFAOYSA-N C(CCCCCCCCCCCCCCCCC)OC(=O)CNC(=O)C1=NC=CC=C1OC Chemical compound C(CCCCCCCCCCCCCCCCC)OC(=O)CNC(=O)C1=NC=CC=C1OC AWCPKCWFUNYKJL-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101700012268 Holin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
BIMZLRFONYSTPT-UHFFFAOYSA-N N-oxalylglycine Chemical class OC(=O)CNC(=O)C(O)=O BIMZLRFONYSTPT-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
206010050207 Skin fibrosis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000012445 acidic reagent Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
238000010640 amide synthesis reaction Methods 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002300 anti-fibrosis Effects 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
NFCPBBXWCPNVDP-UHFFFAOYSA-N butyl 2-aminoacetate;4-methylbenzenesulfonic acid Chemical compound CCCCOC(=O)CN.CC1=CC=C(S(O)(=O)=O)C=C1 NFCPBBXWCPNVDP-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229950005499 carbon tetrachloride Drugs 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
FHSNFOHPTIUXCR-UHFFFAOYSA-N decyl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCCCCCCCCOC(=O)CNC(=O)C1=NC=CC=C1OC FHSNFOHPTIUXCR-UHFFFAOYSA-N 0.000 description 1
230000002950 deficient Effects 0.000 description 1
RRFBMEHULJZFIT-UHFFFAOYSA-N dichloromethane pyridine-2-carboxylic acid Chemical compound ClCCl.N1=C(C=CC=C1)C(=O)O RRFBMEHULJZFIT-UHFFFAOYSA-N 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
XHAGJINGBIBUMU-UHFFFAOYSA-N dodecyl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCCCCCCCCCCOC(=O)CNC(=O)C1=NC=CC=C1OC XHAGJINGBIBUMU-UHFFFAOYSA-N 0.000 description 1
PLGHUJRCHYBFRR-UHFFFAOYSA-N dodecyl 2-aminoacetate;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CCCCCCCCCCCCOC(=O)CN PLGHUJRCHYBFRR-UHFFFAOYSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
102000005396 glutamine synthetase Human genes 0.000 description 1
108020002326 glutamine synthetase Proteins 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
PGFRPABAOPQROU-UHFFFAOYSA-N heptan-4-yl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCC(CCC)OC(=O)CNC(=O)C1=NC=CC=C1OC PGFRPABAOPQROU-UHFFFAOYSA-N 0.000 description 1
VFTZBWRWOZFXIL-UHFFFAOYSA-N heptyl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCCCCCOC(=O)CNC(=O)C1=NC=CC=C1OC VFTZBWRWOZFXIL-UHFFFAOYSA-N 0.000 description 1
BVSLORQDIRBSGX-UHFFFAOYSA-N hexadecyl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CNC(=O)C1=NC=CC=C1OC BVSLORQDIRBSGX-UHFFFAOYSA-N 0.000 description 1
MJOIKRIMMPVECX-UHFFFAOYSA-N hexadecyl 2-aminoacetate;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CCCCCCCCCCCCCCCCOC(=O)CN MJOIKRIMMPVECX-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
UQEHIKBLNMDNSP-UHFFFAOYSA-N hexyl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCCCCOC(=O)CNC(=O)C1=NC=CC=C1OC UQEHIKBLNMDNSP-UHFFFAOYSA-N 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
229940043353 maltol Drugs 0.000 description 1
238000001466 metabolic labeling Methods 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
KSXQRYUHBMAREL-UHFFFAOYSA-N methyl 3-methoxypyridine-2-carboxylate Chemical compound COC(=O)C1=NC=CC=C1OC KSXQRYUHBMAREL-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
GCQHHWDGEFVNDE-UHFFFAOYSA-N nonyl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCCCCCCCOC(=O)CNC(=O)C1=NC=CC=C1OC GCQHHWDGEFVNDE-UHFFFAOYSA-N 0.000 description 1
LFFYDYKNMMFJMR-UHFFFAOYSA-N octyl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCCCCCCOC(=O)CNC(=O)C1=NC=CC=C1OC LFFYDYKNMMFJMR-UHFFFAOYSA-N 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
BMUGOYQTZKXYLC-UHFFFAOYSA-N pentyl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCCCOC(=O)CNC(=O)C1=NC=CC=C1OC BMUGOYQTZKXYLC-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
229940117953 phenylisothiocyanate Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
SINQCIBMYNXTGS-UHFFFAOYSA-N propan-2-yl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound COC1=CC=CN=C1C(=O)NCC(=O)OC(C)C SINQCIBMYNXTGS-UHFFFAOYSA-N 0.000 description 1
SLZJZJGPZQUKMO-UHFFFAOYSA-N propyl 2-[(3-methoxypyridine-2-carbonyl)amino]acetate Chemical compound CCCOC(=O)CNC(=O)C1=NC=CC=C1OC SLZJZJGPZQUKMO-UHFFFAOYSA-N 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
102220240796 rs553605556 Human genes 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000004500 stellate cell Anatomy 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
230000008733 trauma Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000005303 weighing Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

JP09538479A 1996-04-30 1996-04-30 ３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用 Pending JP2000509047A (ja)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP1996/001793 WO1997041103A1 (de)	1996-04-30	1996-04-30	3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel

Publications (1)

Publication Number	Publication Date
JP2000509047A true JP2000509047A (ja)	2000-07-18

Family

ID=8166212

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP09538479A Pending JP2000509047A (ja)	1996-04-30	1996-04-30	３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用

Country Status (7)

Country	Link
EP (1)	EP0900202A1 (de)
JP (1)	JP2000509047A (de)
KR (1)	KR20000065090A (de)
AU (1)	AU5762896A (de)
CA (1)	CA2253282A1 (de)
NO (1)	NO984878L (de)
WO (1)	WO1997041103A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003519215A (ja) *	2000-01-06	2003-06-17	アベンティス・クロップサイエンス・エス・アー	３−ヒドロキシピコリン酸誘導体の調製方法
JP2009541486A (ja) *	2006-06-26	2009-11-26	ザプロクターアンドギャンブルカンパニー	プロリルヒドロキシラーゼ阻害剤および使用方法
WO2016190420A1 (ja) *	2015-05-28	2016-12-01	日本たばこ産業株式会社	糖尿病性腎症を治療又は予防する方法
JP2018504389A (ja) *	2014-12-30	2018-02-15	ダウアグロサイエンシィズエルエルシー	殺真菌活性を有するピコリンアミド

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4590157B2 (ja) *	2001-03-21	2010-12-01	アイシスイノヴェイションリミテッド	アッセイ、方法および手段
DK2298301T3 (en) *	2001-12-06	2018-10-01	Fibrogen Inc	MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
US7588924B2 (en)	2006-03-07	2009-09-15	Procter & Gamble Company	Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
RS54010B1 (sr)	2009-11-06	2015-10-30	Aerpio Therapeutics Inc.	Inhibitori prolil hidroksilaze
WO2012170439A1 (en)	2011-06-06	2012-12-13	The Ohio State University	Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (de)	2011-06-06	2018-03-17
EP2938191B1 (de)	2012-12-28	2018-01-31	Dow AgroSciences LLC	Synergistische fungizide gemische zur pilzbekämpfung in getreidepflanzen
JP2016521747A (ja)	2013-06-13	2016-07-25	アケビアセラピューティクスインコーポレイテッドＡｋｅｂｉａＴｈｅｒａｐｅｕｔｉｃｓＩｎｃ．	貧血治療のための組成物及び方法
MY180626A (en)	2013-11-15	2020-12-03	Akebia Therapeutics Inc	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US20170290333A1 (en)	2014-12-30	2017-10-12	Dow Agrosciences Llc	Picolinamide compounds with fungicidal activity
MX2017008444A (es)	2014-12-30	2017-10-02	Dow Agrosciences Llc	Picolinamidas como fungicidas.
MX2017008439A (es) *	2014-12-30	2017-10-02	Dow Agrosciences Llc	Compuestos de picolinamida con actividad fungicida.
AU2015374459A1 (en)	2014-12-30	2017-06-29	Dow Agrosciences Llc	Picolinamide compounds with fungicidal activity
US10150734B2 (en)	2015-01-23	2018-12-11	Akebia Therapeutics, Inc.	Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en)	2015-04-01	2022-05-10	Akebia Therapeutics, Inc.	Compositions and methods for treating anemia
TW201842851A (zh)	2017-05-02	2018-12-16	美商陶氏農業科學公司	用於穀類中的真菌防治之協同性混合物
TWI774761B (zh)	2017-05-02	2022-08-21	美商科迪華農業科技有限責任公司	用於穀物中的真菌防治之協同性混合物
US11191269B2 (en)	2017-05-02	2021-12-07	Dow Agrosciences Llc	Use of an acyclic picolinamide compound as a fungicide for fungal diseases on turfgrasses
BR102019004480B1 (pt)	2018-03-08	2023-03-28	Dow Agrosciences Llc	Picolinamidas como fungicidas
US11713298B2 (en)	2018-05-09	2023-08-01	Akebia Therapeutics, Inc.	Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
KR20210076072A (ko)	2018-10-15	2021-06-23	코르테바 애그리사이언스 엘엘씨	옥시피콜린아미드의 합성 방법
CN114554848A (zh)	2019-10-18	2022-05-27	科迪华农业科技有限责任公司	用于合成吡啶酰胺的方法
US11524939B2 (en)	2019-11-13	2022-12-13	Akebia Therapeutics, Inc.	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja)	2019-12-10	2021-06-17	田辺三菱製薬株式会社	含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE149485T1 (de) *	1993-11-02	1997-03-15	Hoechst Ag	Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel

1996
- 1996-04-30 CA CA002253282A patent/CA2253282A1/en not_active Abandoned
- 1996-04-30 EP EP96914152A patent/EP0900202A1/de not_active Withdrawn
- 1996-04-30 WO PCT/EP1996/001793 patent/WO1997041103A1/de not_active Ceased
- 1996-04-30 KR KR1019980708679A patent/KR20000065090A/ko not_active Withdrawn
- 1996-04-30 AU AU57628/96A patent/AU5762896A/en not_active Abandoned
- 1996-04-30 JP JP09538479A patent/JP2000509047A/ja active Pending
1998
- 1998-10-19 NO NO984878A patent/NO984878L/no not_active Application Discontinuation

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003519215A (ja) *	2000-01-06	2003-06-17	アベンティス・クロップサイエンス・エス・アー	３−ヒドロキシピコリン酸誘導体の調製方法
JP2009541486A (ja) *	2006-06-26	2009-11-26	ザプロクターアンドギャンブルカンパニー	プロリルヒドロキシラーゼ阻害剤および使用方法
JP2018504389A (ja) *	2014-12-30	2018-02-15	ダウアグロサイエンシィズエルエルシー	殺真菌活性を有するピコリンアミド
JP2018505865A (ja) *	2014-12-30	2018-03-01	ダウアグロサイエンシィズエルエルシー	殺真菌活性を有するピコリンアミド
WO2016190420A1 (ja) *	2015-05-28	2016-12-01	日本たばこ産業株式会社	糖尿病性腎症を治療又は予防する方法
JPWO2016190420A1 (ja) *	2015-05-28	2018-03-15	日本たばこ産業株式会社	糖尿病性腎症を治療又は予防する方法

Also Published As

Publication number	Publication date
NO984878D0 (no)	1998-10-19
WO1997041103A1 (de)	1997-11-06
NO984878L (no)	1998-12-29
CA2253282A1 (en)	1997-11-06
AU5762896A (en)	1997-11-19
EP0900202A1 (de)	1999-03-10
KR20000065090A (ko)	2000-11-06

Publication	Publication Date	Title
JP2000509047A (ja)	2000-07-18	３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用
US6020350A (en)	2000-02-01	3-hydroxypyridine-2-carboxamidoesters, their preparation and their use as pharmaceuticals
US6093730A (en)	2000-07-25	Substituted isoquinoline-3-carboxamides, their preparation and their use as pharmaceuticals
EP0661269B1 (de)	1997-03-26	Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0650960B1 (de)	1997-03-05	Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
RU2129545C1 (ru)	1999-04-27	Амиды сульфамидо- и сульфамидокарбонилпиридин-2-карбоновых кислот, способы их получения и фармацевтическая композиция
US5620996A (en)	1997-04-15	Sulfonamidocarbonyl pyridine-2-carboxesteramides and their pyridine-N-oxide compounds and their use as pharmaceuticals
JPH07278109A (ja)	1995-10-24	スルホンアミドカルボニルピリジン−２−カルボキサミド、それらのピリジン−ｎ−オキシド、それらの製造法および薬剤としてのそれらの使用
JPS6229596A (ja)	1987-02-07	レニン及び酸プロテア−ゼを抑制する４置換炭素原子を含有するペプチド　アミノ−アルコ−ル誘導体、その取得方法及び治療への使用
US4968670A (en)	1990-11-06	Pyridine-2,4- and 2,5-dicarboxylic acid derivatives, a process for their preparation, the use thereof, and medicaments based on these compounds
RU2117660C1 (ru)	1998-08-20	Сложные эфиры ацилсульфонамидо- и сульфонамидопиридин-2-карбоновой кислоты, содержащая их фармацевтическая композиция и способ ее получения
EP0885886B1 (de)	2002-05-29	Pyridincarboxamidderivate
RU1836349C (ru)	1993-08-23	Замещенные диамиды 2,4- или 2,5-пиридиндикарбоновой кислоты, обладающие ингибирующей лизин- или пролингидроксилазу активностью
HUP9903414A2 (en)	2000-07-28	3-alkoxypyridine-2-carboxylic acid amide esters,their preparation and their use as drugs
MXPA97009438A (es)	1998-10-30	Ester-amidas de acido 3-hidroxi-piridina-2-carboxilico, su preparacion y su utilizacion como medicamentos
CN1216981A (zh)	1999-05-19	3－烷氧基吡啶－2－酰胺酯,它们的制备及药用
HK1008851A (en)	1999-05-21	3-hydroxypyridine-2-carboxamidoesters, their preparation and their use as pharmaceuticals
IL101257A (en)	1998-03-10	2, 4 - and -2,5 - pyridine dicarboxyamides, a process for preparing them, the use thereof and pharmaceutical compositions based on these compounds